292 related articles for article (PubMed ID: 29091447)
21. Frozen in Time: Kinetically Stabilized Amorphous Solid Dispersions of Nifedipine Stable after a Quarter Century of Storage.
Theil F; Anantharaman S; Kyeremateng SO; van Lishaut H; Dreis-Kühne SH; Rosenberg J; Mägerlein M; Woehrle GH
Mol Pharm; 2017 Jan; 14(1):183-192. PubMed ID: 28043131
[TBL] [Abstract][Full Text] [Related]
22. Structural evolution of indomethacin particles upon milling: time-resolved quantification and localization of disordered structure studied by IGC and DSC.
Planinsek O; Zadnik J; Kunaver M; Srcic S; Godec A
J Pharm Sci; 2010 Apr; 99(4):1968-81. PubMed ID: 20049752
[TBL] [Abstract][Full Text] [Related]
23. [Advances in the quantitative analytical methods of drug polymorphism].
Ma LW; Du W; Zhao CS
Yao Xue Xue Bao; 2011 Aug; 46(8):896-903. PubMed ID: 22007512
[TBL] [Abstract][Full Text] [Related]
24. Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy.
Heinz A; Savolainen M; Rades T; Strachan CJ
Eur J Pharm Sci; 2007 Nov; 32(3):182-92. PubMed ID: 17716878
[TBL] [Abstract][Full Text] [Related]
25. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
26. Characterization of Phase Separation Propensity for Amorphous Spray Dried Dispersions.
McNamara D; Yin S; Pan D; Crull G; Timmins P; Vig B
Mol Pharm; 2017 Feb; 14(2):377-385. PubMed ID: 28068097
[TBL] [Abstract][Full Text] [Related]
27. Raman mapping for kinetic analysis of crystallization of amorphous drug based on distributional images.
Ueda H; Ida Y; Kadota K; Tozuka Y
Int J Pharm; 2014 Feb; 462(1-2):115-22. PubMed ID: 24368105
[TBL] [Abstract][Full Text] [Related]
28. Determination of amorphous content in the pharmaceutical process environment.
Savolainen M; Jouppila K; Pajamo O; Christiansen L; Strachan C; Karjalainen M; Rantanen J
J Pharm Pharmacol; 2007 Feb; 59(2):161-70. PubMed ID: 17270070
[TBL] [Abstract][Full Text] [Related]
29. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
Fini A; Cavallari C; Ospitali F
Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
[TBL] [Abstract][Full Text] [Related]
30. Kinetics Study of Cocrystal Formation Between Indomethacin and Saccharin Using High-Shear Granulation With In Situ Raman Spectroscopy.
Tanaka R; Hattori Y; Ashizawa K; Otsuka M
J Pharm Sci; 2019 Oct; 108(10):3201-3208. PubMed ID: 31279736
[TBL] [Abstract][Full Text] [Related]
31. The contribution of Raman spectroscopy to the analysis of phase transformations in pharmaceutical compounds.
Hédoux A; Guinet Y; Descamps M
Int J Pharm; 2011 Sep; 417(1-2):17-31. PubMed ID: 21256937
[TBL] [Abstract][Full Text] [Related]
32. Crystallization pathways and kinetics of carbamazepine-nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies.
Seefeldt K; Miller J; Alvarez-Núñez F; Rodríguez-Hornedo N
J Pharm Sci; 2007 May; 96(5):1147-58. PubMed ID: 17455346
[TBL] [Abstract][Full Text] [Related]
33. Polymorph characterization of active pharmaceutical ingredients (APIs) using low-frequency Raman spectroscopy.
Larkin PJ; Dabros M; Sarsfield B; Chan E; Carriere JT; Smith BC
Appl Spectrosc; 2014; 68(7):758-76. PubMed ID: 25014842
[TBL] [Abstract][Full Text] [Related]
34. Quantification of Process Induced Disorder in Milled Samples Using Different Analytical Techniques.
Zimper U; Aaltonen J; McGoverin CM; Gordon KC; Krauel-Goellner K; Rades T
Pharmaceutics; 2010 Feb; 2(1):30-49. PubMed ID: 27721341
[TBL] [Abstract][Full Text] [Related]
35. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy.
Savolainen M; Kogermann K; Heinz A; Aaltonen J; Peltonen L; Strachan C; Yliruusi J
Eur J Pharm Biopharm; 2009 Jan; 71(1):71-9. PubMed ID: 18590816
[TBL] [Abstract][Full Text] [Related]
36. Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement.
Branham ML; Moyo T; Govender T
Eur J Pharm Biopharm; 2012 Jan; 80(1):194-202. PubMed ID: 21906676
[TBL] [Abstract][Full Text] [Related]
37. Comparison of amorphous states prepared by melt-quenching and cryomilling polymorphs of carbamazepine.
Guinet Y; Paccou L; Danède F; Willart JF; Derollez P; Hédoux A
Int J Pharm; 2016 Jul; 509(1-2):305-313. PubMed ID: 27237427
[TBL] [Abstract][Full Text] [Related]
38. Effect of milling conditions on the solid-state conversion of ranitidine hydrochloride form 1.
Chieng N; Zujovic Z; Bowmaker G; Rades T; Saville D
Int J Pharm; 2006 Dec; 327(1-2):36-44. PubMed ID: 16949221
[TBL] [Abstract][Full Text] [Related]
39. An example of how to handle amorphous fractions in API during early pharmaceutical development: SAR114137--a successful approach.
Petzoldt C; Bley O; Byard SJ; Andert D; Baumgartner B; Nagel N; Tappertzhofen C; Feth MP
Eur J Pharm Biopharm; 2014 Apr; 86(3):337-50. PubMed ID: 24075979
[TBL] [Abstract][Full Text] [Related]
40. In situ co-amorphisation of arginine with indomethacin or furosemide during immersion in an acidic medium - A proof of concept study.
Petry I; Löbmann K; Grohganz H; Rades T; Leopold CS
Eur J Pharm Biopharm; 2018 Dec; 133():151-160. PubMed ID: 30339888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
